1 Multiplex PCR detection of enteric pathogens in a community-

2 based birth cohort in Ecuador: comparison of xTAG-GPP and

3 TaqMan array card assays

4

- 5 Stuart Torres Ayala¹*, Lesly Simbaña Vivanco¹*, Nikolina Walas²*, Kelsey Jesser³,
- 6 Nicolette A. Zhou³, Christine S. Fagnant-Sperati³, Hadley R. Burroughs⁴, Gwenyth O. Lee⁵,
- 7 Joseph N.S. Eisenberg⁶, Gabriel Trueba¹, Karen Levy³, Benjamin F. Arnold^{4,7,8} #
- 8
- 9 Affiliations:
- 10 ¹ Instituto de Microbiología, Universidad San Francisco de Quito, Quito, Ecuador
- 11 ² Department of Environmental Health Sciences, University of California, Berkeley, CA, USA
- 12 ³ Department of Environmental and Occupational Health Sciences, University of Washington, Seattle,
- 13 WA, USA
- 14 ⁴ Francis I. Proctor Foundation, University of California, San Francisco, CA, USA
- 15 ⁵ Rutgers Global Health Institute, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA
- 16⁶ Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
- 17 ⁷ Department of Ophthalmology, University of California, San Francisco, CA, USA
- 18 ⁸ Institute for Global Health Sciences, University of California, San Francisco, CA, USA
- 19
- 20 * STA, LSV, and NW contributed equally
- 21
- 22 # Corresponding Author:
- 23 Benjamin F. Arnold
- 24 Associate Professor
- 25 F.I. Proctor Foundation
- 26 University of California, San Francisco
- 27 <u>ben.arnold@ucsf.edu</u>
- 28 +1 415 514 3227
- 29
- 30 **Running head:** Comparison of TaqMan and xTAG-GPP assays
- 31
- 32 **Keywords**: multiplex PCR, bacteria, viruses, protozoans, enteric pathogens
- 33
- 34
- 35 Abstract

We compared the performance of two multiplex platforms, Luminex xTAG Gastrointestinal Pathogen Panel[®] and TaqMan Array Card, against a panel of 14 enteric pathogen targets in a community-based birth cohort in Ecuador. We found high levels of agreement and similar prevalence estimates across most pathogens.

41 Introduction

42 Enteric pathogens account for a substantial burden of disease among children in low- and middle-43 income countries (1). Multiplex gPCR assays such as the Luminex xTAG Gastrointestinal 44 Pathogen Panel® (GPP) and the TaqMan Array Card (TAC) enable efficient detection of 45 pathogens in stool compared with single-pathogen PCR or gPCR testing and represent a major 46 advance in enteric pathogen diagnostics (2,3). Multiplex assays were originally developed and 47 have been used extensively in clinical settings for early infection diagnosis (4). Epidemiological 48 studies are increasingly using these assays to characterize the burden of enteric infections, 49 diarrheal etiology, and intervention impacts (5,6), and as the number of these population-based 50 studies continues to grow, there is an increasing need to better understand the comparability of 51 different multiplex assays. GPP is a commercial assay that screens for 15 pathogens while the TAC assay is customized by individual labs and, for this project, included 30 pathogens. We 52 53 compared the performance of the two multiplex assays, GPP and TAC, against a panel of 14 54 overlapping viral, bacterial, and protozoan enteric pathogen targets in a community-based birth 55 cohort in Ecuador, a high transmission setting.

56 Methods

57 Study Design

58 ECoMiD is an ongoing longitudinal birth cohort study based in Esmeraldas Province in northern-59 coastal Ecuador (7). The protocol was reviewed and approved by institutional review boards at 60 University of Washington (#STUDY00014270), Emory University (#IRB00101202), Universidad 61 San Francisco de Quito (#2018–022M), and University of California, San Francisco (#21-33932), 62 and all participants provided informed consent, with re-consent for each stool sample collection. 63 The study has enrolled 521 children from communities across a rural-urban gradient and collected 64 periodic stool samples from study subjects from ages one week to 24 months. To potentially 65 increase the efficiency of the assay comparison, we considered samples that had been analyzed 66 by the TAC assay, run earlier in the study, and had a positive result for at least one pathogen in 67 the GPP assay (n=485 samples). We then selected a random sample stratified by age (6, 12, 18 68 months) and location (rural accessible by river, rural accessible by road, intermediate, and urban) 69 to be representative of the cohort (n=156, 13 per stratum). We estimated that 156 samples would 70 provide 80% power to determine a difference between assays per target using McNemar's test 71 assuming a 5% alpha and sensitivities of 95.8% (TAC) and 89.6% (GPP), with conditional sensitivity

of 98.9% for TAC given a positive by GPP (8) based on TAC and GPP parameters for rotavirus in
 clinical samples (2).

74

75 Laboratory Methods

Stool samples were collected by caregivers in a small, insulated container and field staff collected samples within 1 hour of sample production if the sample was not refrigerated, or within 3 hours if the sample was refrigerated and stored in –196 °C portable liquid nitrogen tanks. Samples were transported monthly to the Universidad San Francisco de Quito for long-term storage at –80 °C.

Nucleic acids from stool samples (180-220 mg) were extracted using Qiagen QIAamp Fast DNA
Stool Mini Kit (QIAGEN, Germantown, MD) into a proprietary elution buffer, with an added bead
beating step during sample lysis (Jesser et al. *in review*). During the extraction process MS2 and
PhHV were added as an external control assessment of extraction and amplification efficiency.
ZymoBIOMICS Spike-in Controls (Zymo Research) were used as positive controls. Extracted
DNA was aliguoted and stored at –80 °C.

87

For GPP testing samples were amplified and hybridized according to the Luminex xTAG GPP kit protocol. xTAG[®] RNAse-free water was used as a negative control and three stocks of known pathogen DNA (ZeptoMetrix NATtrol[™] GI Verification Panel 2) were used as positive controls. GPP gene targets are proprietary but median fluorescence intensity (MFI) values used to determine positivity are available (**Supplemental Table 1**).

93

94 For TAC testing, extracted nucleic acids from stool samples (20 µL) were combined with AgPath-95 ID One-Step RT-PCR master mix (50 µL) (Applied Biosystems, Waltham, MA), AgPath-ID One-96 Step RT-PCR enzyme (4 µL) (Applied Biosystems), and nuclease-free water (26 µL) (Applied 97 Biosystems) and analyzed for pathogen gene targets using TAC (ThermoFisher Scientific, 98 Waltham, MA) (Supplemental Table 2) with the following cycling conditions: 45°C for 20 minutes, 99 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute on a 100 QuantStudio 7 Flex instrument (ThermoFisher Scientific). Positive controls included PhHV, MS2 101 and the pan E. coli gene target uidA as well as customized plasmids expressing all known assay 102 targets (ThermoFisher Scientific and Azenta Life Sciences, South Plainfield, NJ). Nuclease-free 103 water was used as a no template control on each card. Samples with cycle threshold (Ct) value 104 \leq 35 for any of the gene targets for a pathogen were classified as positive.

106 Statistical Methods

We estimated pathogen target prevalence and agreement with exact, binomial 95% confidence intervals for the 14 targets. Agreement of pathogen target-level results between the two assays was assessed using McNemar's test and Cohen's kappa (9). Tests did not adjust for multiple comparisons. We examined MFI and Ct values for samples with discordant TAC and GPP results, positive by one assay and negative by the other, to determine if discordance was more likely with lower quantity of sample DNA detected. Analyses were conducted using R (v4.4.0; R Core Team 2024).

114 **Results**

115 Two selected samples failed on the GPP assay, so the analysis included 154 samples. Overall, 116 infection prevalence was similar between assays (Figure 1) and agreement was >85% for 13 of 117 14 pathogen targets (Table 1). There were differences in detection between TAC and GPP 118 assavs for five targets (McNemar's P<0.05), with higher prevalence by TAC for rotavirus. 119 Campylobacter spp., and ST-ETEC, and higher prevalence by GPP for Shigella spp., and 120 Salmonella spp.. Accounting for agreement due to chance, six targets differed with a kappa 121 coefficient below 0.6 (**Table 1**), however kappa statistics are influenced by outcome prevalence 122 so comparison between pathogens should be made with caution given the wide range of 123 prevalence observed (10). There was very poor agreement between assays for Salmonella, 124 where the GPP assay classified 81% of samples as positive while the TAC assay classified 8% 125 positive (Figure 1, Table 1). The rank order of prevalence was similar between assays with the 126 exception of rotavirus, ST-ETEC, and Salmonella. Across targets, discordance between assays 127 was more likely for pathogens with MFI values just over the positivity cutoff for GPP (for GPP+, 128 TAC-, Supplemental Figure 1) or Ct value just below 35 for TAC (for TAC+, GPP-, 129 Supplemental Figure 2).

130 Discussion

Prior diagnostic comparison studies of the GPP and TAC assays have focused on tests of diarrheal samples in clinical settings, and found that the assays were broadly comparable and had good test performance as clinical diagnostics (2,6). This study aimed to evaluate the assay performance using community-based samples from young children and found the two assays were broadly comparable.

136

137 Consistent negative and positive controls on all GPP plates ruled out lab contamination as an 138 explanation for the poor agreement between assays for *Salmonella*. Previous studies have noted 139 high rates of *Salmonella* false positives by GPP (11,12) and at least one large-scale study 140 excluded GPP *Salmonella* results on this basis (6). The discrepancy between GPP and TAC may 141 result from differences in the oligonucleotide primers for the pathogen targets used for 142 *Salmonella*.

143

144 This study had limitations. First, GPP uses proprietary target sequences — although we assume 145 that differences between assay target sequences was an important underlying cause for larger 146 discrepancies, such as for Salmonella and rotavirus, we could only infer this through examination 147 of MFI and Ct values (Supplemental Figures 1, 2). Because we had no gold standard measure of infection across the 14 pathogens, we focused on agreement between the TAC and GPP 148 149 assays but were unable to estimate their diagnostic characteristics, such as sensitivity and 150 specificity. We focused on pathogen-specific comparisons between assays and did not assess 151 co-infections or number of pathogens detected, which could be of interest in high transmission 152 settings. We intentionally over-sampled stools that were positive by TAC to at least one target on 153 the GPP assay to increase power for the comparison, but our sampling approach could inflate 154 estimates of prevalence. Finally, we did not consider diarrhea symptoms in this analysis, but 155 results should be representative of pediatric samples (both symptomatic and asymptomatic) in a 156 high transmission setting.

157

Despite these caveats, this study had many strengths. We tested samples collected in a community-based cohort, with children enrolled across an urban-rural gradient at the ages when enteric pathogen burden is highest. The assays included pathogens thought to be major causes of diarrheal disease burden in lower resource settings (5), and we observed a broad range of pathogen prevalence in this study. The results thus should inform similar epidemiologic field studies.

164

Conclusion: This comparative analysis provides important guidance on comparing data from
 TAC and GPP assays in non-clinical, pediatric samples for both within and across cohort
 analyses.

169 Footnote information

- Funding: This work was funded by the National Institutes of Health (R01A137679 to KL andJNSE, R01AI162867 to BFA).
- 172
- 173 **Competing interests:** The authors declare no competing interests.
- 174
- 175 **Data availability:** Data and replication files are available through the Open Science Framework:
- 176 <u>https://osf.io/jh64t/</u>.
- 177
- 178 **Conference presentation:** The results will be presented at the 2024 meeting of the American
- 179 Society of Tropical Medicine and Hygiene, Oral Presentation Abstract #8373, November 17, 2024,
- 180 New Orleans, LA, USA.

181 References

- Calvopiña M, Eisenberg JNS, Atherton R, Trueba G, Andrade T, Eguiguren M, et al.
 Identifying Etiological Agents Causing Diarrhea in Low Income Ecuadorian Communities.
 Am J Trop Med Hyg. 2014 Sep 3:91(3):563–9.
- Chhabra P, Gregoricus N, Weinberg GA, Halasa N, Chappell J, Hassan F, et al.
 Comparison of three multiplex gastrointestinal platforms for the detection of gastroenteritis
 viruses. J Clin Virol. 2017 Oct;95:66–71.
- Chang LJ, Hsiao CJ, Chen B, Liu TY, Ding J, Hsu WT, et al. Accuracy and comparison of
 two rapid multiplex PCR tests for gastroenteritis pathogens: a systematic review and meta analysis. BMJ Open Gastroenterol. 2021 Feb;8(1):e000553.
- Khare R, Espy MJ, Cebelinski E, Boxrud D, Sloan LM, Cunningham SA, et al. Comparative
 Evaluation of Two Commercial Multiplex Panels for Detection of Gastrointestinal Pathogens
 by Use of Clinical Stool Specimens. Gilligan PH, editor. J Clin Microbiol. 2014
 Oct;52(10):3667–73.
- Platts-Mills JA, Liu J, Rogawski ET, Kabir F, Lertsethtakarn P, Siguas M, et al. Use of
 quantitative molecular diagnostic methods to assess the aetiology, burden, and clinical
 characteristics of diarrhoea in children in low-resource settings: a reanalysis of the MAL-ED
 cohort study. Lancet Glob Health. 2018 Dec;6(12):e1309–18.
- Knee J, Sumner T, Adriano Z, Anderson C, Bush F, Capone D, et al. Effects of an urban sanitation intervention on childhood enteric infection and diarrhea in Maputo, Mozambique: A controlled before-and-after trial. eLife. 2021 Apr 9;10:e62278.
- Lee GO, Eisenberg JNS, Uruchima J, Vasco G, Smith SM, Van Engen A, et al. Gut
 microbiome, enteric infections and child growth across a rural–urban gradient: protocol for
 the ECoMiD prospective cohort study. BMJ Open. 2021 Oct;11(10):e046241.
- Connor RJ. Sample size for testing differences in proportions for the paired-sample design.
 Biometrics. 1987 Mar;43(1):207–11.
- 9. McHugh ML. Interrater reliability: the kappa statistic. Biochem Medica. 2012;22(3):276–82.
- Sim J, Wright CC. The Kappa Statistic in Reliability Studies: Use, Interpretation, and
 Sample Size Requirements. Phys Ther. 2005 Mar 1;85(3):257–68.
- 210 11. Duong VT, Phat VV, Tuyen HT, Dung TTN, Trung PD, Minh PV, et al. Evaluation of
 211 Luminex xTAG Gastrointestinal Pathogen Panel Assay for Detection of Multiple Diarrheal
 212 Pathogens in Fecal Samples in Vietnam. Richter SS, editor. J Clin Microbiol. 2016
 213 Apr;54(4):1094–100.
- Kellner T, Parsons B, Chui L, Berenger BM, Xie J, Burnham CAD, et al. Comparative
 Evaluation of Enteric Bacterial Culture and a Molecular Multiplex Syndromic Panel in
 Children with Acute Gastroenteritis. Ledeboer NA, editor. J Clin Microbiol. 2019
- 217 Jun;57(6):e00205-19.

218 Figures and Tables

219



220

Figure 1: Infection prevalence for 14 enteric pathogens measured by Luminex xTAG Gastrointestinal Panel (GPP) and TaqMan Array Card (TAC) assays. Analysis includes 154 samples from children ages 6 to 18 months in Esmeraldas Province, Ecuador 2022-2023. An asterisk indicates McNemar's P<0.05 for difference between the two assays. Supplemental Table 3 includes numerical estimates. Created with script: https://osf.io/4dteg.

226

Table 1: Summary of multiplex PCR test results for Luminex xTAG Gastrointestinal
Pathogen Panel (GPP) and TaqMan Array Card (TAC). Test results from 154 samples
measured among children at ages 6 to 18 months in Esmeraldas Province, Ecuador, 2022-2023.
Test results are summarized by whether they were positive (+) or negative (-) by GPP and TAC.
Methods include details on estimation of agreement, Cohen's Kappa, and McNemar's test for
differences between assays. Created with script: https://osf.io/4dteq.

Assay Target	GPP - TAC -	GPP + TAC -	GPP - TAC +	GPP + TAC +	Agreement % (95% Cl)	Kappa (95% Cl)	McNemar's p-value
Viruses							
Adenovirus (40/41)	137	4	3	10	95.5 (90.9, 98.2)	0.72 (0.56, 0.9)	0.71
Norovirus GI	147	0	3	4	98.1 (94.4, 99.6)	0.72 (0.57, 0.9)	0.08
Norovirus GII	138	1	6	9	95.5 (90.9, 98.2)	0.70 (0.54, 0.9)	0.06
Rotavirus	142	0	11	1	92.9 (87.6, 96.4)	0.14 (0.06, 0.2)	<0.01
Bacteria							
Campylobacter spp.	107	3	17	27	87.0 (80.7, 91.9)	0.65 (0.50, 0.8)	<0.01
LT-ETEC	87	10	9	48	87.7 (81.4, 92.4)	0.74 (0.58, 0.9)	0.82
ST-ETEC	130	1	15	8	89.6 (83.7, 93.9)	0.45 (0.32, 0.6)	<0.01
STEC stx1	134	5	1	14	96.1 (91.7, 98.6)	0.80 (0.65, 1.0)	0.10
STEC stx2	142	6	1	5	95.5 (90.9, 98.2)	0.57 (0.42, 0.7)	0.06
Shigella spp.	128	7	1	18	94.8 (90.0, 97.7)	0.79 (0.63, 0.9)	0.03
Salmonella spp.	30	112	0	12	27.3 (20.4, 35.0)	0.04 (-0.00, 0.1)	<0.01
Protozoa							
Cryptosporidium spp.	130	11	7	6	88.3 (82.2, 92.9)	0.34 (0.18, 0.5)	0.35
Entamoeba histolytica	151	2	1	0	98.1 (94.4, 99.6)	-0.01 (-0.16, 0.1)	0.56
<i>Giardia</i> spp.	119	4	11	20	90.3 (84.4, 94.4)	0.67 (0.51, 0.8)	0.07

238 Supplementary Information

239

240 Supplemental Table 1: Luminex Gastrointestinal Pathogen Panel (GPP) assay targets and

241 corresponding median fluorescence intensity (MFI) thresholds for positivity

242

Analyte	Threshold for positivity (MFI)
Adenovirus 40/41	≥ 150
Camplobacter	≥ 150
C. difficile Probe-1	≥ 150
C. difficile Probe-2	≥ 150
Cryptosporidium	≥ 250
E. coli O157	≥ 150
E. histolytica	≥ 250
ETEC probe-1	≥ 200
ETEC probe-2	≥ 200
Giardia	≥ 250
Norovirus Probe-1	≥ 200
Norovirus Probe-2	≥ 350
Rotavirus A	≥ 150
Salmonella Probe-1	≥ 100,000 (POS), < 300 (NEG)
Salmonella Probe-2	≥ 200
STEC Probe-1	≥ 150
STEC Probe-2	≥ 150
Shigella	≥ 150
V. cholerae	≥ 150

245 Supplemental Table 2: TaqMan Array Card (TAC) assay gene targets and corresponding

forward (F) and reverse (R) primers and probe (P) sequences.

Organism	Gene Target	Sequence		
Adenovirus (40/41)	Fiber gene	F, AACTTTCTCTCTTAATAGACGCC R, AGGGGGCTAGAAAACAAAA P, FAM-CTGACACGGGCACTCT-MGB		
Norovirus GI	ORF1-ORF2	F, CGYTGGATGCGNTTYCATGA R, CTTAGACGCCATCATCATTYAC P, FAM-TGGACAGGAGATCGC-MGB		
Norovirus GII	ORF1-ORF2	F, CARGARBCNATGTTYAGR TGGATGAG R, TCGACGCCATCTTCATTCACA P, FAM-TGGGAGGGCGATCGCAATCT-MGB		
Rotavirus	NSP3	F, ACCATCTWCACRTRACCCTCTATGAG R, GGTCACATAACGCCCCTATAGC P, FAM-AGTTAAAAGCTAACACTGTCAAA-MGB		
Camplobacte r jejuni	cadF	F, CWGCTAAACCATARAAATAAAATTTCTCAC R, YTTTGAAGGTAATTTAGATATGGATAATCG P, VIC-CATTTTGAYGATTTTTGGCTTGA-MGB		
	hipO	F, CTTGCGGTCATGATGGACATAC R, AGCACCACCCAAACCCTCTTCA P, FAM-TGCTTGCTGCAAAGTATT-MGB		
Camplobacte r coli	GlyA	F, AAACCAAAGCTTATCGTGTGC R, AGTGCAGCAATGTGTGCAAT P, FAM-TAAGCTCCAACTTCATCCG-MGB		
LT-ETEC	LT	F, TTCCCACCGGATCACCAA R, CAACCTTGTGGTGCATGATGA P, FAM-CTTGGAGAGAAGAACCCT-MGB		
ST-ETEC	STh	F, GCTAAACCAGYAGRGTCTTCAAAA R, CCCGGTACARGCAGGATTACAACA P, FAM-TGGTCCTGAAAGCATGAA-MGB		
	STp	F, TGAATCACTTGACTCTTCAAAA R, GGCAGGATTACAACAAAGTT P, FAM-TGAACAACACATTTTACTGCT-MGB		
STEC	stx1	F, ACTTCTCGACTGCAAAGACGTATG R, ACAAATTATCCCCTGWGCCACTATC P, FAM-CTCTGCAATAGGTACTCCA-MGB		
	stx2	F, CCACATCGGTGTCTGTTATTAACC R, GGTCAAAACGCGCCTGATAG P, FAM-TTGCTGTGGATATACGAGG-MGB		
Shigella spp.	ipaH	F, CCTTTTCCGCGTTCCTTGA		

		R, CGGAATCCGGAGGTATTGC P, VIC-CGCCTTTCCGATACCGTCTCTGCA-MGB
Salmonella enterica	ttr	F, CTCACCAGGAGATTACAACATGG R, AGCTCAGACCAAAAGTGACCATC P, FAM-CACCGACGGCGAGACCGACTTT-MGB
Salmonella enterica serovar Typhi	tviB	F, TGTGGTAAAGGAACTCGGTAAA R, GACTTCCGATACCGGGATAATG P, VIC-TGGATGCCGAAGAGGTAAGACGAGA-MGB
	sty0201	F, CGCGAAGTCAGAGTCGACATAG R, AAGACCTCAACGCCGATCAC P, FAM-CAGCCTGCTCCAGAACA-MGB
Cryptosporidi um hominus	LIB13	F, TCCTTGAAATGAATATTTGTGACTCG R, AAATGTGGTAGTTGCGGTTGAAA P, FAM-CTTACTTCGTGGCGGCGT-MGB
Cryptosporidi um parvum	LIB13	F, TCCTTGAAATGAATATTTGTGACTCG R, TTAATGTGGTAGTTGCGGTTGAAC P, FAM-TATCTCTTCGTAGCGGCGTA-MGB
Cryptosporidi um spp.	18S	F, GGGTTGTATTTATTAGATAAAGAACCA R, AGGCCAATACCCTACCGTCT P, FAM-TGACATATCATTCAAGTTTCTGAC-MGB
Entamoeba histolytica	18S	F, ATTGTCGTGGCATCCTAACTCA R, GCGGACGGCTCATTATAACA P, FAM-TCATTGAATGAATTGGCCATTT-MGB
<i>Giardia</i> spp.	18S	F, GACGGCTCAGGACAACGGTT R, TTGCCAGCGGTGTCCG P, FAM-CCCGCGGCGGTCCCTGCTAG-MGB

Supplemental Table 3: Infection prevalence for 14 enteric pathogens measured by Luminex
 xTAG Gastrointestinal Panel (GPP) and TaqMan Array Card (TAC) assays. Stool samples
 were tested from children at ages 6, 12, and 18 months old in Esmeraldas Province, Ecuador,
 2022-2023. Created with script: https://osf.io/4dteq.

255

GPP Target	Ν	GPP pos	GPP Prev (95% CI)	TAC pos	TAC Prev (95% CI)
Viruses					
Adenovirus_40_41	154	14	9.1 (5.1, 14.8)	13	8.4 (4.6, 14.0)
Norovirus_GI	154	4	2.6 (0.7, 6.5)	7	4.5 (1.8, 9.1)
Norovirus_GII	154	10	6.5 (3.2, 11.6)	15	9.7 (5.6, 15.6)
Rotavirus_A	154	1	0.6 (0.0, 3.6)	12	7.8 (4.1, 13.2)
Bacteria					
Campylobacter	154	30	19.5 (13.5, 26.6)	44	28.6 (21.6, 36.4)
ETEC_LT	154	58	37.7 (30.0, 45.8)	57	37.0 (29.4, 45.2)
ETEC_ST	154	9	5.8 (2.7, 10.8)	23	14.9 (9.7, 21.6)
STEC_stx1	154	19	12.3 (7.6, 18.6)	15	9.7 (5.6, 15.6)
STEC_stx2	154	11	7.1 (3.6, 12.4)	6	3.9 (1.4, 8.3)
Shigella	154	25	16.2 (10.8, 23.0)	19	12.3 (7.6, 18.6)
Salmonella	154	124	80.5 (73.4, 86.5)	12	7.8 (4.1, 13.2)
Protozoa					
Cryptosporidium	154	17	11.0 (6.6, 17.1)	13	8.4 (4.6, 14.0)
Entamoeba_histolytica	154	2	1.3 (0.2, 4.6)	1	0.6 (0.0, 3.6)
Giardia	154	24	15.6 (10.2, 22.3)	31	20.1 (14.1, 27.3)

Supplemental Figure 1: Median fluorescence intensity (MFI) values for pathogen targets detected by the Luminex GPP Assay. Results are categorized according to TaqMan Array Card (TAC) and Luminex xTAG Gastrointestinal Pathogen Panel (GPP) assay sample results, for positive (+) and negative (-) detection for each target. Created with script: <u>https://osf.io/hfv5r</u>.



264 265

266 Supplemental Figure 2: Cycle threshold (Ct) values for pathogen associated gene targets

267 **detected by the TAC Assay**. Multiple gene targets were used for some enteric pathogens in the

268 TaqMan Array Card (TAC) panel. In each comparison, the top row label identifies the Luminex

269 xTAG Gastrointestinal Pathogen Panel (GPP) target, and the second row identifies the TAC

270 target. Results are categorized according to TAC and GPP assay sample results, for positive (+)

and negative (–) detection for each GPP target. Created with script: <u>https://osf.io/hfv5r</u>.

